Rubius Therapeutics

Rubius Therapeutics, Inc. is dedicated to developing red cell therapeutics (RCTs) aimed at treating severe diseases, including cancer, rare conditions, and autoimmune disorders. The company is advancing several key programs, such as RTX-240 and RTX-224 for cancer treatment, RTX-aAPC for both solid and hematological cancers, RTX-321 for HPV-positive tumors, and RTX-T1D for type 1 diabetes. Founded in 2013 and based in Cambridge, Massachusetts, Rubius Therapeutics harnesses its proprietary rubius erythrocyte design cellular therapy platform to create a new class of medicines. The company's innovative approach is rooted in scientific exploration and aims to address unmet medical needs through transformative therapeutic solutions.